Wallace Eli M.
SEC insider (Form 3/4/5 filer). CIK 0001776352. Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc. (BBOT). 4 reported Form 4/5 transactions since Sep 2024; latest on Jan 1, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Wallace Eli M. has filed insider reports for
- BridgeBio Oncology Therapeutics, Inc. (BBOT): Director, Officer, Chief Executive Officer
Wallace Eli M.
CIK: 0001776352
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BridgeBio Oncology Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
1.1M shares- - Dec 10, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
1.1M shares- - Oct 2, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
1.6M shares- - Aug 26, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
499.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award Stock Option (Right to Buy) | 1,114,400 | - | - | Direct |
| Dec 10, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 1,114,400 | - | - | Direct |
| Oct 2, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award Stock Option (Right to Buy) | 1,614,400 | - | - | Direct |
| Aug 26, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award Stock Option (Right to Buy) | 499,731 | - | - | Direct |
1-4 of 4 transactions